Chronic kidney disease and its complications part 3C

Kidney cartoon 4

 

Chronic kidney disease and its complications:

ANAEMIA

  • Treatment with erythropoetin stimulating agent must be commenced by or in consultation with a nephrologist. There are several erythropoetins currently available for this indication. All available as pre-fillid syringes and are usually administered subcutaneously to pre-dyalisis or peritoneal dialysis patient

 

  • Erythropoetin stimulating agent are available either through hospital pharmacies or on authorithy prescription under section 100 of the pharmaceutical benefits scheme for “treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100g/L, where intrinsic kidney disease as assessed by a nephrologist, is the primary cause of the anaemia”.

 

  • It is recommended that erythropoetin stimulating agent therapy is used with great caution, if at all, in chronic kidney disease patients with active malignancy. If used in this setting, target Hb levels are lower in those patients, and the lowest dose of erythropoetin stimulating agent is used to prevent blood transfusion,
Advertisements

About azaleaazelia

A nice person... :)
This entry was posted in Tak Berkategori. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s